Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 3/20 | 0.56 |
| ▸ | TLR2 | O60603 | 2/20 | 0.53 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 5/20 | 0.46 |
| ▸ | HTR2B | P41595 | 2/20 | 0.46 |
| ▸ | TERT | O14746 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23746435 | 1.00 | PRCP (0.56) | PRCPTLR2DPP7HTR2CHTR2B | |
| SCHEMBL23746434 | 1.00 | PRCP (0.56) | PRCPTLR2DPP7HTR2CHTR2B | |
| SCHEMBL4598210 | 0.95 | PRCP (0.51) | PRCPTLR2DPP7HTR2CHTR2B | |
| SCHEMBL13306209 | 0.88 | PRCP (0.55) | PRCPTLR2DPP7HTR2CHTR2B | |
| SCHEMBL27329772 | 0.85 | PRCP (0.56) | PRCPTLR2DPP7HTR2CHTR2B | |
| SCHEMBL27329773 | 0.85 | PRCP (0.56) | PRCPTLR2DPP7HTR2CHTR2B | |
| SCHEMBL7274579 | 0.83 | PRCP (0.61) | PRCPTLR2DPP7HTR2CHTR2B | |
| SCHEMBL6954674 | 0.83 | PRCP (0.50) | PRCPTLR2DPP7HTR2CHTR2B | |
| SCHEMBL7309284 | 0.83 | PRCP (0.61) | PRCPTLR2DPP7HTR2CHTR2B | |
| SCHEMBL615383 | 0.82 | PRCP (0.68) | PRCPTLR2DPP7HTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0346847-A2 | Amino acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1989-12-20 | — | — | EP | claimed |
| US-20210244712-A1 | METHODS FOR TREATING PATIENTS WITH CANCER HAVING DEFECTS IN CYCLIN D REGULATION | NYSNOBIO IRELAND DAC (IE) | 2021-08-12 | — | — | US | disclosed |
| US-5446161-A | Protease inhibitor, viricides | HOFFMANN-LA ROCHE INC. (US) | 1995-08-29 | — | — | US | disclosed |
| EP-0346847-B1 | Amino acid derivatives | HOFFMANN LA ROCHE (CH) | 1994-05-11 | — | — | EP | disclosed |
| EP-0346847-A2 | Amino acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1989-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210244712-A1 | METHODS FOR TREATING PATIENTS WITH CANCER HAVING DEFECTS IN CYCLIN D REGULATION | TP53, RB1, CDK1 | PRCP 1836/4885TLR2 4688/4885DPP7 3774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.